Placebo (for Rimonabant)
Sponsors
Sanofi
Conditions
ArteriosclerosisCardiovascular DiseaseCarotid Artery PlaqueDiabetes Mellitus Type 2Diabetes Mellitus, Type 2Fatty LiverMetabolic SyndromeMetabolic Syndrome X
Phase 3
Atherosclerosis Underlying Development Assessed by Intima-Media Thickness in Patients on Rimonabant
TerminatedNCT00228176
Start: 2005-08-31End: 2009-04-30Updated: 2016-05-20
Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes
TerminatedNCT00263042
Start: 2005-12-31End: 2009-04-30Updated: 2016-05-20
VIsceral Fat Reduction Assessed by CT-scan On RImonabAnt
CompletedNCT00299325
Start: 2006-02-28End: 2008-07-31Updated: 2016-06-06
Rimonabant In Prediabetic Subjects To Delay Onset Of Type 2 Diabetes
TerminatedNCT00325650
Start: 2006-05-31End: 2009-03-31Updated: 2016-05-18
Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients With Oral Anti-diabetic Drug
TerminatedNCT00478595
Start: 2007-04-30End: 2009-02-28Updated: 2016-06-06
Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients on Diet and Exercise
TerminatedNCT00478972
Start: 2007-04-30End: 2009-01-31Updated: 2016-06-08
An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients Without Diabetes
TerminatedNCT00576667
Start: 2008-01-31End: 2009-02-28Updated: 2016-05-18
An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients With Type 2 Diabetes
TerminatedNCT00577148
Start: 2008-02-29End: 2009-02-28Updated: 2016-05-18
Effect of Rimonabant and Metformin Combination on Glycemic Control in Patients With Type 2 Diabetes
TerminatedNCT00690456
Start: 2008-05-31End: 2009-02-28Updated: 2016-05-18